Skip to main content

Bipolar Disorders

Taking psychiatric medication did not hamper weight loss in people who participated in a structured weight loss program, researchers recently reported online in the journal Obesity.
Alkermes plc is expanding its New Drug Application (NDA) for the investigational drug ALKS 3831—a combination of the antipsychotic olanzapine and the novel molecular entity samidorphan—to include the treatment of bipolar I disorder as well as schizophrenia, the drugmaker recently announced.
Lumateperone, an investigational drug from Intra-Cellular Therapies, Inc., posted varied results in two phase 3 clinical trials evaluating it as a monotherapy for major depressive episodes associated with bipolar disorder.
People with bipolar disorder who smoke tobacco, whether or not they have other substance use disorders, are at a higher risk of repeating a suicide attempt, according to a study published in the Journal of Affective Disorders.
Allergan Plc's Vraylar won US regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said.
Back to Top